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Common practices associated with the use of cryopreserved
hematopoietic progenitor cells (HPC) include measuring the
viability of the thawed cells from a sample derived from the
thawed product, and thawing cells at the patient’s bedside out
of concern for possible toxicity of DMSO in the post-thaw liq-
uid cell suspension. The former practice carries the risk of dis-
covering excess cell death when it is too late to correct, and
the concomitant risk of non-engraftment. The latter practice
carries all of the risks associated with manipulating cells in a
non-controlled environment including risk of contamination
and lack of suitable containment in the event of failure of a cry-
ostorage container. In an effort to reduce risks associated with
cell cryostorage, we are currently examining the validity of
measuring CD34 viability from cells frozen in retention vials
concomitantly with product freezing. We are also examining
the stability of HPC being held in cryostorage medium from
1 to 24 hours post thaw. We present here our results from a
pilot study performed on six bags of cells, previously identified
for discard due to death of the intended recipients. Six bags of
HPC and associated retention vials, frozen for 5 to 12 years,
were selected at random from the pool of discarded products
and de-identified per guidelines for discard of medical waste.
CD34+ cells were identified using a modification of the ISHAGE
method, and dead cells were identified by infiltration with the
fluorochrome dye 7-AAD. CD34+ cells stored in retention vials
were 94§11 percent viable, and CD34+ cells stored in bags
were 96§7 percent viable. A Wilcoxan matched pairs test
yielded p=0.6, indicating that these results were not different.
Percent viable CD34+ cell recovery, relative to the known num-
ber of CD34+ cells per mL originally frozen, was determined
immediately following thawing, and following 1, 2, 4 and
24 hours remining in thawed cryostorage medium, with recov-
eries (mean § std. dev.) of 88 § 31, 76 § 33, 62 § 28, 88 § 41,
and 49 § 26 percent respectively. These preliminary results
suggest that viable CD34 percent as measured from a retention
vial may serve as a predictor of viability at thawing of it’s asso-
ciated product, and also that HPC held in cryostorage medium
post thaw retain viability for at least four hours post thawing.
Based on these results we are continuing these studies.236
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Patients with relapsed/refractory diffuse large B-cell lym-
phoma (DLBCL) have poor treatment outcomes when treated
with traditional chemoimmunotherapy. Superior outcomes
have been observed with the 2 CAR-T cell products approved
by the US FDA; tisagenlecleucel (CTL109) and axicabtagene cil-
oleucel (Axi-cel) with 12 months overall survival rates of 49%
and 59% respectively. The 2 major acute toxicities of these
therapies are cytokine release syndrome (CRS) and neurotoxic-
ity. The incidence of grade 3 or higher neutropenia, anemia,
and thrombocytopenia was 78%, 43%, and 38% in patients
treated with axi-cel. Little is known regarding the patterns and
outcomes of these cytopenias. Here we present our prelimi-
nary experience on the patterns and outcomes of cytopenias in
32 patients who received commercially-available CAR-T cell
therapy at our institution.
We retrospectively reviewed all DLBCL patients receiving either
CTL109 or axi-cel between January and September 2018 at our
institution. All patients received a conditioning regimen of low-
dose cyclophosphamide and fludarabine, followed by CAR-T infu-
sion. Persistent cytopenias were defined as incomplete absolute
neutrophil count (<1£ 109/L), Hb (<12 g/dL) or platelet count
(<100£ 109/L) recovery after day 28 of CAR-T cell infusion.
Treatment response was assessed with PET-CT imaging and clas-
sified according to International Working Group Criteria.
The median age of patients was 59 years (range, 23-80); 63%
were male, 4 patients (13%) received CTL109 and 28 (87%)
received axi-cel. Twenty-two patients (69%) had a 3 month
follow up imaging for assessment of response, of whom
7 patients (32%) achieved complete response (CR), 6 patients
(27%) achieved partial response (PR), and 9 patients (41%)
had progressive disease (PD). Persistent neutropenia was
observed in 3 patients (9%), while persistent thrombocyto-
penia was seen in 21 cases (65%) and persistent anemia was
the most common with a frequency of 72% (23/32 cases).
Median time to neutrophil, platelet and Hb recoveries were
11 days (range, 5-218 days), 59.5 days (range, 4-241 days),
and 76 days (range, 0-218 days), respectively. Filgrastim was
used in 15 (47%) patients to facilitate neutrophil recovery.
Twenty-three patients (72%) experienced neurotoxicity, of
whom 11 (34%) had grade 3-4 toxicity. The frequency of CRS
was 94% (29 out of 32 patients), with grade 3-4 CRS observed
in 4 cases (12.5%). We observed no significant association
between CRS and persistent cytopenias.
In our preliminary series of 32 patients, persistent anemia and
thrombocytopenia were more common than neutropenia after
CAR-T cell therapy. However, most of these patients required
growth factor support for neutrophil recovery. Longer duration
of follow up is necessary to determine the impact of persistent
cytopenias on outcomes and survival after CAR-T cell therapy.
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Donor Lymphocyte Infusion from G-CSF-Primed,
UnmanipulatedWhole Blood Is Safe and Improves
Chimerism in HLA-Matched and Haploidentical
Transplantation
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Figure 1. Cumulative Incidence of GVHD in DLI vs CD34+ selected SCB patients.
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Introduction: Donor lymphocyte infusion (DLI) is a useful
therapy for mixed chimerism (MC) and measurable residual
disease (MRD) after allogeneic transplantation (HSCT). Multi-
ple DLI products can be obtained through apheresis and cryo-
preservation, but their costs can be prohibitive in developing
countries. T-cells in whole blood units can reach 1£ 106/kg
in healthy donors and are increased after G-CSF exposure. The
ideal CD3+ cell dose remains undefined.
Objectives: We aim to assess the safety and efficacy of
G-CSF-primed whole blood units (WB-DLI) in peripheral
blood HLA-matched sibling (MSD) and haploidentical
(Haplo) transplant recipients.
Methods: Adults who received WB-DLI at any time after HSCT
due to relapse, MRD, MC or poor graft function were included.
Patients with active graft-versus-host disease (GVHD) were
excluded. Donors received filgrastim 5 mg/kg QD (days 1-3) fol-
lowed by a 450 mL whole blood draw on day 4 with cross-
matching and lymphocyte quantification. For patients with
major/bidirectional ABO mismatch without group switch or
a mixed field reaction, a reactive major crossmatch was an
absolute contraindication. WB-DLI was infused fresh and
unmanipulated in an outpatient basis. Concurrent chemother-
apy was allowed. Disease and chimerism were assessed on day
30 and 60, respectively. GVHD prophylaxis included oral cyclo-
sporine/tacrolimus tapered in 60 days.
Results: Fourteen patients received a single WB-DLI, median
age was 32 years (range, 16-67), 50% were women. Most com-
mon diagnoses were ALL, (n=5) and AML (n=5), followed by
MDS (n=2), NHL (n=1) and CML (n=1). Nine had were Haplo
grafts, while 4 were MSD. Indication for WB-DLI was relapse in
6 patients, 3 had MRD, 4 MC and 1 had poor graft function.
Median chimerism pre-WB-DLI was 72% (range, 38-100%).
Median mononuclear cell count obtained was 32£ 10x6/kg
(range, 9-74), while median CD3+ cell count was 6.7£ 106/Kg
(range, 5.2-19). No immediate severe adverse effects were
observed. Febrile non-hemolytic reaction occurred in n=4. No
complications were observed in n=4 ABO mismatch cases.
Overall 50% responded; chimerism improved in 50%, with a
median increase of 28% (range, 9-53%). Median post-DLI chi-
merism was 92.5% (range, 20-100). Regarding patients treated
for relapse or MRD 4/9 responded (33%). Overall 8/14 patients
relapsed (57%) with 12-month progression free survival of
27.5% which was significantly lower in relapsed/MRD patients
(log rank test p=0.042). Overall survival at 12 months was esti-
mated at 61.2%. Three developed aGVHD, 2 grade III/IV in
a median of 13 days (range, 7-38). Four died due to relapse.
Median follow-up was 5 months (0.6-20.1 months). The cost of
performing WB-DLI was $350 USD per unit.
Conclusions: DLI obtained from GCSF-primed whole-blood is
safe and affordable. It improves mixed chimerism, while it is
less effective for overt relapse, similarly to DLI obtained
through standard methods.238
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Introduction: Allogeneic hematopoietic stem cell transplantation
(SCT) is a widely used to treat refractory and relapsed hematologi-
cal malignancies. Additional CD34+ selected cells, or stem cell
boosts (SCB), and CD3+ T cells, or donor lymphocyte infusions
(DLI) are often administered to treat poor hematopoietic graft
function or relapse of the underlyingmalignancy, respectively, fol-
lowing SCT. Although the T cell dose in SCB and DLI vary by more
than 3 logs, graft-versus-host disease (GVHD) can be a major
cause of morbidity and mortality in patients who receive addi-
tional post-transplant donor T cells. The purpose of this study is to
test the hypothesis that the incidence of GVHD after infusions of
additional donor T cells is associated with the cumulative inci-
dence of GVHD in patients who received DLI vs SCB.
Methods: A retrospective cohort study was conducted on conse-
cutive patients at Emory University Hospital who received a DLI
or CD34+ cell-selected SCB from January 2000 to September 2016.
Excluding patients with incomplete records, 46 DLI and 15 SCB
patients were analyzed for post-infusion GVHD and 2-year post-
infusion survival. SPSS Statistics was used to conduct a binary
logistic regression on DLI and SCB patients in order to determine
significant variation inGVHD incidence per relevant covariates.
Results: The median doses of CD3+ T cells were
18£ 10E6 cells/kg and 0.054£ 10E6 cells/kg for DLI and SCB
recipients, respectively. 73% of SCB patients received prophy-
lactic immunosuppressive drug therapy versus 20% of DLI
patients (Table 1). In spite of receiving less than 0.3% of the
T cell dose of DLI recipients, SCB recipients had a 60% cumula-
tive incidence of GVHD by 2-years of follow-up versus 37% in
DLI patients (Figure 1; p =0.142). Binary regression models
showed that GVHD incidence did not vary significantly with
the dose of T cells and other covariates, except age in the DLI
group (Tables 2 and 3). Overall survival at 2 years was 48% for
